Squamous cell carcinoma - Skivepitelcancer
☆ I Stiftung Warentest-resultaten 2022 från Tyskland var konsumentnöjdheten med ModelDerm bara något lägre än med betalda telemedicinkonsultationer.
Squamous cell carcinoma well differentiated ― En intilliggande aktinisk keratos observeras.
References
Squamous cell carcinoma (SCC) är den näst vanligaste hudcancern i USA, efter basal cell carcinoma. Det börjar vanligtvis från precancerösa lesioner som kallas actinic keratosis och kan spridas till andra delar av kroppen. Den främsta orsaken är exponering för ultraviolett (UV) strålning från solen, som ackumuleras med tiden. Behandlingen innebär vanligtvis kirurgiskt avlägsnande, särskilt för SCC på huvud och nacke. Strålbehandling är ett alternativ för äldre patienter eller de som inte kan opereras. Immunsuppression ökar risken för SCC. Även om det är sällsynt kan SCC sprida sig, särskilt hos patienter med försvagat immunförsvar. Regelbundna kontroller och solskydd är viktigt för dem med SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) är den näst vanligaste cancersjukdomen hos människor, och antalet ökar. Även om CSCC vanligtvis visar ett benignt kliniskt beteende, kan det spridas både lokalt och till andra delar av kroppen. Forskare har identifierat specifika vägar involverade i CSCC-utveckling, vilket leder till nya behandlingar. Det höga antalet mutationer och ökad risk hos immunsupprimerade patienter har föranlett utvecklingen av immunterapi. Denna recension tittar på de genetiska rötterna av CSCC och de senaste behandlingarna som riktar sig mot specifika molekyler och immunsystemet.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnos och behandling
#Dermoscopy
#Skin biopsy